Mobocertinib: A potential treatment for nsclc with egfr exon 20 insertions

Abstract

Summary: Amivantamab is the only FDA-approved therapy for non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions. Unfortunately, patients eventually develop progression of disease on this therapy, and most do not respond to this treatment. In this issue of Cancer Discovery, Gonzalvez and colleagues and Riely and colleagues highlight preclinical and early clinical data supporting mobocertinib as a potentially efficacious agent for NSCLC with EGFR exon 20 insertions.